doi:https://doi.org/

References:

Timp J.F., Braekkan S.K., Versteeg H.H., Cannegieter S.C. Epidemiology of cancer-associated venous thrombosis. Blood 2013;122:1712—1723.
Ay C., Pabinger I., Cohen A.T. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 2017;117:219—230.
Prandoni P., Lensing A.W.A., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484—3488.
Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146—153.
Lee A.Y.Y., Kamphuisen P.W., Meyer G., et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677—686.
Lyman G.H., Bohlke K., Falanga A. American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 2015;11:e442—e444.
Farge D., Debourdeau P., Beckers M., et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013;11:56—70.
Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149:315—352.
Khorana A.A., Yannicelli D., McCrae K.R., et al. Evaluation of US prescription pat- terns: are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res 2016;145:51—53.
Kahn S.R., Springmann V., Schulman S., et al. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting: the Recovery Study. Thromb Haemost 2012;108:493—498.
van Es N., Coppens M., Schulman S., et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124:1968—1975.
Bleker S.M.A., Brekelmans M.P.A., Eerenberg E.S., et al. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists: an individual patient data meta-analysis. Thromb Haemost 2017;117:1944—1951.
Francis C.W., Kessler C.M., Goldhaber S.Z., et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 2015;13:1028—1035.